Sebastian Gensior

Every so often, I wonder if I’m shouting into the void. Not in the performative, social media outrage kind of way, but in the actual sense of watching bad ideas flourish, seeing obvious failures repeat themselves, and knowing that most people will keep playing along—because it’s easier.

When a venture capital (VC) firm or a legal team evaluates an early-stage biotech or pharma startup, due diligence is critical. The stakes are high: investments hinge on scientific credibility, commercial viability, and the ability to navigate regulatory hurdles. This guide details a forensic, red-team approach to uncovering

LinkedIn. The once-practical platform for professional networking has evolved into a peculiar blend of motivational seminar, humblebrag arena, and corporate confessional. You’ve seen the posts: “Starting my next adventure, which taught me so much about resilience and growth.” Or the classic ski-trip reflection: “Connecting with nature in

I have a confession to make: I’m fascinated by failure. Not in a morbid, schadenfreude sort of way, but in the way one might study an iceberg—not for the visible peak but for the vast, hidden bulk beneath. And in no industry is that unseen mass more significant

Mentoring: It’s Not Just a LinkedIn Title Mentoring is having a moment. If you’ve scrolled through LinkedIn recently, you’ve probably noticed an explosion of people adding “mentor” to their titles. It sounds noble, even glamorous—guiding the next generation, shaping the future, giving back. But let’s

Overall survival (OS) has long been considered the gold standard in oncology trials. Defined as the time from treatment initiation until death from any cause, OS provides a direct and intuitive measure of a therapy's impact on patient longevity. However, as the costs of oncology treatments skyrocket, even

Probability of Pricing and Access Success (PPAS) is an emerging metric that evaluates the likelihood of a drug achieving favorable pricing and market access post-approval. Unlike traditional metrics such as Probability of Success (POS) or Probability of Launch (POL), PPAS explicitly incorporates factors often neglected in drug development analyses—

Probability of Technical Success (PTS) is a metric that evaluates the likelihood that a drug candidate will successfully navigate clinical trials. Unlike broader metrics such as Probability of Success (POS) or Probability of Launch (POL), PTS focuses narrowly on the technical aspects of clinical development, including efficacy, safety, and adherence

The MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index (USD) is a key benchmark for the biotech and pharmaceutical industry. Comprising 72 large- and mid-cap stocks across 23 markets, this index provides a perspective on companies involved in drug development, biotechnology innovation, and life sciences tools and services. Index

Killing a project is easy. There’s a laundry list of reasons why something “shouldn’t move forward”: it’s too expensive, not aligned with strategy, lacks clear ROI, or simply isn’t the “right time.” Most organizations are primed to find these flaws—whether it’s a risk-averse